Baseline characteristics of the UKPSSR and ASSESS cohorts by baseline subgroup membership. Data displayed are either counts with percentages in brackets or median values with 25th and 75th percentiles in brackets.
| LSB | DDF | HSB | P value | |||
| n | UKPSSR | 39 (14.2%) | 56 (20.4%) | 108 (39.4%) | 71 (25.9%) | |
| ASSESS | 65 (19.5%) | 43 (12.9%) | 141 (42.2%) | 85 (25.4%) | ||
| Age | UKPSSR | 59 (49–66) | 63 (51–68) | 64 (54–70) | 57 (50–65) | p=ns (Wilcoxon) |
| ASSESS | 59 (45–67) | 56 (48–64) | 58 (51–67) | 58 (52–68) | p=ns (Wilcoxon) | |
| Sex | UKPSSR | 34F 5M | 51F 5M | 98F 10M | 62F 9M | p=ns (Fisher’s) |
| ASSESS | 55F 10M | 41F 2M | 130F 11M | 84F 1M | p=0.007 (Fisher’s) | |
| ESSPRI | UKPSSR | 2 (1.3–2.7) | 5 (4–5.7) | 6 (4.7–7.3) | 6.7 (5.3–8) | p<0.001 (Wilcoxon) |
| ASSESS | 2.33 (1.67–2.67) | 5 (4.33–6) | 6 (5–7.3) | 6.7 (5.5–7.7) | p=0.001 (Wilcoxon) | |
| ESSDAI | UKPSSR | 2.5 (0–7.25) | 3.5 (1–6) | 4 (2–8) | 5 (2–8) | p=ns (Wilcoxon) |
| ASSESS | 3 (1–6.8) | 3 (2–5) | 3 (1–9) | 3 (2–7) | p=ns (Wilcoxon) | |
| Anti-Ro positivity | UKPSSR | 30 pos 9 neg (76.92%) | 51 pos 5 neg (91.07%) | 76 pos 32 neg (70.37%) | 50 pos 21 neg (70.42%) | p=0.01 (Fisher’s) |
| ASSESS | 44 pos 19 neg (69.84%) | 31 pos 12 neg (72.09%) | 68 pos 61 neg (52.71%) | 46 pos 35 neg (56.79%) | p=0.04 (Fisher’s) | |
| Anti-La positivity | UKPSSR | 24 pos 15 neg (61.53%) | 33 pos 19 neg 2 ND (58.93%) | 45 pos 50 neg 1 ND (41.67%) | 38 pos 24 neg 1 ND (53.52%) | p=0.01 (Fisher’s) |
| AECG Years | UKPSSR | 3 (1–7.5) | 4 (1–12.25) | 4 (1–9) | 3 (1–10) | p=ns (Wilcoxon) |
| ASSESS | 5 (1–8) | 6 (3–10) | 5 (2–10) | 7 (3–10) | p=ns (Wilcoxon) | |
| BMI | UKPSSR | 25.4 (22.5–29) | 25.2 (22.3–28.9) | 26.3 (23.3–32.3) | 27 (23.6–29.7) | p=ns (Wilcoxon) |
| ASSESS | 22 (20–24) | 22 (20–25) | 23 (21–28) | 25 (21–31) | p=0.0001 (Wilcoxon) | |
| C4 | UKPSSR | 0.2 (0.16–0.25) | 0.21 (0.17–0.26) | 0.23 (0.18–0.28) | 0.23 (0.17–0.3) | p=ns (Wilcoxon) |
| EQ-5D UK utility | UKPSSR | 0.88 (0.76–1) | 0.8 (0.7–0.85) | 0.69 (0.59–0.76) | 0.62 (0.03–0.69) | p<0.001 (Wilcoxon) |
| CCI | UKPSSR | 3.5 (2.6–5) | 4 (2–6) | 6 (3–8) | 5 (3–8) | p<0.001 (Wilcoxon) |
| HCQ Past Present | UKPSSR | 3 (7.69%) 11 (28.20%) | 11 (19.64%) 15 (26.78%) | 23 (21.29%) 49 (48.37%) | 16 (22.53%) 30 (42.25%) | p=0.62 (Fisher’s) |
| Polypharmacy | UKPSSR | 2 (1– 2) | 2 (2– 3) | 3 (2–4) | 3 (2–4) | p<0.001 (Wilcoxon) |
AECG, American European Consensus Group; ASSESS, Assessment of Systemic Signs and Evolution of Sjogren’s Syndrome ; BMI, Body Mass Index; C4, complement factor C4; CCI, Chronic Conditions Index; DDF, dryness dominant with fatigue; EQ-5D, EuroQual Health Related Quality of Life UK Utility value (five dimensions); ESSDAI, EULAR Sjogren’s Syndrome Disease Activity Index; ESSPRI, EULAR Sjogren’s Syndrome Patient Reported Index; HCQ, Hydroxychloroquine; HSB, high symptom burden; LSB, low symptom burden; PDF, pain dominant with fatigue ; UKPSSR, United Kingdom Primary Sjögren’s Syndrome Registry.